AstraZeneca tozorakimab Phase III COPD success
Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The positive results position tozorakimab as a potential best-in-class COPD treatment, expanding AstraZeneca's respiratory franchise and likely boosting its revenue outlook. The FDA Priority Review acceptance accelerates potential market entry, positively impacting AstraZeneca's stock and the broader respiratory biologics market.
AstraZeneca announced positive full results from the Phase III OBERON and TITANIA trials of tozorakimab, a first-in-class IL-33-targeting monoclonal antibody, in chronic obstructive pulmonary disease (COPD). Tozorakimab 300mg every four weeks reduced moderate and severe exacerbations by 29-34% in former smokers and 29-30% in the overall population versus placebo, on top of inhaled standard of care. It was the first biologic to show efficacy across all blood eosinophil counts and smoking statuses, and also reduced mucus plugging. The data were presented at the European Respiratory Society Congress and published in the The New England Journal of Medicine. The United States — Food and Drug Administration accepted the Biologics License Application for Priority Review, with a PDUFA date expected in Q1 2027. Tozorakimab is also under regulatory review in the European Union and China, and is being studied in asthma and severe viral lower respiratory tract disease.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard